Orbit and Evergreen partner to advance radiopharmaceuticals development
04 Apr 2023
PDCLicense out/in
Preview
Source: Pharmaceutical Technology
Under the deal, both firms will focus on developing peptide libraries. Credit: WikimediaImages from Pixabay.
Evergreen Discovery has partnered with Orbit Discovery to discover specific cell-targeting peptides and advance the development of new radiopharmaceuticals.
Both firms will focus on creating peptide libraries, as well as hit identification and hit validation to verify cell surface-binding properties.
The Orbit platform will also conduct in vitro transcription conversion from DNA-encoded libraries on beads.
This enables the screening of vast libraries, by employing fluorescence-activated cell sorting (FACS)-based methodologies.
In addition, Evergreen will support the development of the peptides for use in clinical environments.
Evergreen Discovery chief scientific officer Dr Thomas Reiner said: “We are very pleased to be partnering with Orbit Discovery and capitalising on its technology and expertise in both chemistry and biology to drive innovation and expansion of our radiopharmaceutical candidate pipeline.
“The requirement for more direct screening technologies is key to successful drug development, and we see Orbit as a stepping stone in attaining our goals in a rapid timeframe.”
The latest collaboration aims to tap the expanding radiopharmaceuticals industry, which has seen the development of a number of targeting moieties.
These moieties are capable of enabling specific binding to a tumour target, with the ability to localise the treatment to diseased tissues.
Peptides are considered to be an important delivery method as they have the capability to minimise off-target toxicities.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.